1. First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin (SQUIRE)
ClinicalTrials.gov Identifier: NCT00981058
The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab (IMC-11F8), given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving patient disease than the standard chemotherapy combination alone.
NB
Saint John
ON
Weston
Brampton
QC
Montreal
SK
Saskatoon
3. Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT01109524
The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine
NB
Moncton Hospital
ON
Credit Valley Hospital, Mississauga
Toronto East General Hospital, Toronto
Sudbury regional Hospital, Sudbury
QC
Centre de Sante et de services sociaux de Rimouski-Neigette, Rimouski
4. An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Carcinoma
ClinicalTrials.gov Identifier: NCT01232452
The primary purpose of this study is to evaluate the hypothesis that cixutumumab given in combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as first-line therapy for patients with advanced nonsquamous non-small cell lung carcinoma (NSCLC).
ON
Oshawa
QC
Montreal
5. Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) (ECLIPSE)
ClinicalTrials.gov Identifier: NCT01082549
Purpose: To evaluate the overall survival (OS) of patients with advanced squamous cell lung cancer receiving the combination of gemcitabine/carboplatin either with or without Iniparib
AB
Edmonton
ON
Toronto
London
Oshawa
QC
Greenfield Park
Sainte-Foy
6. A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)
ClinicalTrials.gov Identifier: NCT01154140
Purpose: This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.
AB
Edmonton
ON
Oshawa
QC
Montreal General Hospital
Jewish General Hospital
St. Mary’s Hospital
Royal Victoria Hospital
Sainte-Foy
7. A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT01268059
Purpose: The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).
ON
Ottawa
8. A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov Identifier: NCT01160744
The purpose of this study is to determine if patients with Stage 4 non-small cell lung cancer have a better outcome when treated with 1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin then when treated with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin alone.
ON
Toronto
QC
Montreal
9. Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
ClinicalTrials.gov Identifier: NCT01450761
The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.
ON
Toronto
QC
Montreal
10. Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
ClinicalTrials.gov Identifier: NCT01221077
A multicenter, randomized, double-blind, placebo-controlled, phase 2 study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung cancer (NSCLC) with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene who are Chemonaive.
ON
Juravinski Cancer Center, Hamilton
Princess Margaret Hospital, Toronto
London Health Sciences Center, London
QC
Jewish general Hospital, Montreal
11. LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
ClinicalTrials.gov Identifier: NCT01466660
This is a randomised, open-label, phase IIb trial of afatinib to compare to gefitinib in first-line treatment setting with patients who are having epidermal growth factor receptor mutation positive advanced adenocarcinoma of the lung.
AB
Edmonton
BC
Surrey
Vancouver
ON
Oshawa
Ottawa
QC
Montreal
12. A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung
ClinicalTrials.gov Identifier: NCT01218516
This randomized, placebo-controlled, multicenter study will test the hypothesis that farletuzumab can add to the efficacy of a platinum containing doublet in Stage IV adenocarcinoma of the lung.
ON
Royal Victoria Hospital, Barrie
Princess Margaret Hospital, Toronto
QC
Jewish General Hospital, Montreal